CMV Vaccine-A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor

Grants and Contracts Details

StatusFinished
Effective start/end date4/8/145/27/21

Funding

  • Astellas Pharma Global Development Incorporated: $178,387.00